WO2013145966A1 - 吸収性物品 - Google Patents

吸収性物品 Download PDF

Info

Publication number
WO2013145966A1
WO2013145966A1 PCT/JP2013/054369 JP2013054369W WO2013145966A1 WO 2013145966 A1 WO2013145966 A1 WO 2013145966A1 JP 2013054369 W JP2013054369 W JP 2013054369W WO 2013145966 A1 WO2013145966 A1 WO 2013145966A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
chain hydrocarbon
top sheet
absorbent article
blood
Prior art date
Application number
PCT/JP2013/054369
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
竜也 田村
野田　祐樹
央 橋野
裕和 目黒
Original Assignee
ユニ・チャーム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニ・チャーム株式会社 filed Critical ユニ・チャーム株式会社
Priority to CN201380028095.1A priority Critical patent/CN104334134B/zh
Publication of WO2013145966A1 publication Critical patent/WO2013145966A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/51104—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections
    • A61F13/51108—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections the top sheet having corrugations or embossments having one axis relatively longer than the other axis, e.g. forming channels or grooves in a longitudinal direction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/51113—Topsheet, i.e. the permeable cover or layer facing the skin comprising an additive, e.g. lotion or odour control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties

Definitions

  • the present invention relates to absorbent articles such as sanitary napkins, panty liners, incontinence pads, incontinence liners and the like.
  • the absorbent article which applied the skin care composition to the top sheet of the main part is known as prior art (for example, patent documents 1).
  • An apertured formed film is used for the top sheet of the absorbent article.
  • the absorbent article is provided with a flap formed by extending the top sheet in the width direction.
  • the skin care composition applied to the top sheet of the main body is an open portion of the top sheet in the folded wing. May penetrate the wing through In this case, the penetration between the top sheet and the back sheet in the wing may be weakened by the infiltrated skin care composition, and the top sheet may peel off from the back sheet when the absorbent article is used for a long time.
  • An object of the present invention is to provide an absorbent article in which the composition constituting the top sheet penetrates the wing when the wing is folded, thereby preventing the sheet constituting the wing from peeling off.
  • the present invention adopts the following configuration in order to solve the above-mentioned problems. That is, the present invention has a longitudinal direction and a width direction, and includes a main body portion and a pair of wing portions extending in the width direction from both side edges of the main body portion, and the main body portion is liquid permeable provided on the skin side
  • An absorbent article comprising: a non-woven non-woven top sheet, a liquid-impermeable back sheet provided on the clothing side, and a liquid-retaining absorbent provided between the top sheet and the back sheet,
  • the sheet is provided with a protrusion in the excretory opening contact area at least in contact with the wearer's excretory opening on the skin side surface, and the top sheet is a composition in which a predetermined composition is applied at least in the excretory opening contact area It further comprises an application area.
  • Another embodiment of the present invention has a longitudinal direction and a width direction, and includes a main body portion and a pair of wing portions extending in the width direction from both side edges of the main body portion, and the main body portion is liquid permeable provided on the skin side
  • An absorbent article comprising: a non-woven non-woven top sheet, a liquid-impermeable back sheet provided on the clothing side, and a liquid-retaining absorbent provided between the top sheet and the back sheet,
  • the compression section formed by embossing from the sheet to the inside of the absorber is provided at least in the excretory opening contact area on the skin side surface that abuts the excretory opening of the wearer, and the top sheet at least The area is provided with a composition application area to which a predetermined composition is applied.
  • FIG. 1 is a partially broken plan view of an embodiment of the absorbent article of the present invention.
  • FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG.
  • FIG. 3 is a view for explaining the projection and the recess of the top sheet in the absorbent article according to the embodiment of the present invention.
  • FIG. 4 is a figure for demonstrating the method to form a protrusion and a recessed part in a top sheet.
  • FIG. 5 is a view for explaining an absorbent article according to an embodiment of the present invention in which the wings are folded for packaging.
  • FIG. 6 is a perspective view of a package including the absorbent article of one embodiment of the present invention.
  • FIG. 7 is a schematic cross-sectional view showing a cross section taken along line DD of FIG.
  • FIG. 8 is a view for explaining the protrusion, the recess, and the opening of the top sheet in a modified example of the absorbent article according to one embodiment of the present invention.
  • FIG. 9 is a figure for demonstrating the method to form the opening part of the absorbent article modification of one Embodiment of this invention.
  • FIG. 10 is a view for explaining a protrusion of a top sheet in a modified example of the absorbent article of one embodiment of the present invention.
  • FIG. 11 is a view for explaining the protrusion, the recess, and the opening of the top sheet in a modified example of the absorbent article according to one embodiment of the present invention.
  • FIG. 12 is a view for explaining a modified example of the absorbent article of one embodiment of the present invention.
  • FIG. 13 is a figure for demonstrating the modification of the absorbent article of one Embodiment of this invention.
  • FIG. 14 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin in which the top sheet contains avian C2L oil fatty acid glyceride.
  • FIG. 15 is a photomicrograph of menstrual blood with or without a blood modifying agent.
  • FIG. 16 is a diagram for explaining a method of measuring surface tension.
  • FIG. 1 is a partially broken plan view of an absorbent article according to an embodiment of the present invention
  • FIG. 2 is a schematic cross-sectional view taken along the line AA of FIG.
  • the absorbent article 1 has a liquid-permeable top sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 provided on the clothing side (non-skin contact side), and a top sheet 2 and the back sheet 3 are provided with a liquid-retaining absorbent body 4 and a body portion 10 provided with liquid-impermeable side sheets 5 provided on both sides in the width direction of the top sheet 2; It includes a pair of wing portions 6 provided with a side sheet 5 and a back sheet 3 extending in the width direction from both side edges.
  • symbol 61 shows the root of the wing part 6 (boundary between the main-body part 10 and the wing part 6).
  • a straight line connecting two points where the width of the absorbent article 1 suddenly increases on both sides in the longitudinal direction of the wing portion 6 can be regarded as the root 61 of the wing portion 6.
  • An adhesive portion 7 is provided on the surface of the wing portion 6 on the clothes side.
  • an adhesive portion 7 is provided on the surface of the main body portion 10 on the clothes side.
  • the width direction of the absorbent article 1 is the X direction
  • the longitudinal direction is the Y direction.
  • the plane direction of the absorbent article 1 is the XY direction.
  • the top sheet 2 of the main body 10 may be extended in the width direction without providing the side sheet 5, and the wing 6 may include the top sheet 2 and the back sheet 3.
  • the shape of the main body portion 10 is not particularly limited as long as it is a shape that conforms to the shape of a female body and an underwear, such as a rectangular shape, an oval shape, and an hourglass shape.
  • the longitudinal dimension in the outer shape of the main body 10 is preferably 100 to 500 mm, more preferably 150 to 350 mm. Further, the dimension in the width direction of the outer shape of the main body 10 is preferably 30 to 200 mm, more preferably 40 to 180 mm.
  • the top sheet 2 transfers body fluid such as urine and menstrual blood discharged from the wearer to the absorber 4.
  • the top sheet 2 is wholly or partially liquid-permeable, and the liquid-permeable area of the top sheet 2 is a liquid-permeable non-woven fabric, a woven fabric, a resin film having a large number of liquid-permeable holes, or a large number of meshes. It can be formed of a net-like sheet or the like.
  • the top sheet 2 is preferably made of non-woven fabric.
  • any of natural fibers and chemical fibers can be used.
  • natural fibers include cellulose such as ground pulp, cotton and the like.
  • chemical fibers include regenerated celluloses such as rayon and fibril rayon, semi-synthetic celluloses such as acetate and triacetate, thermoplastic hydrophobic chemical fibers, and thermoplastic hydrophobic chemical fibers subjected to hydrophilization treatment.
  • thermoplastic hydrophobic chemical fibers include single fibers such as polyethylene (PE), polypropylene (PP) and polyethylene terephthalate (PET), fibers obtained by graft polymerization of PE and PP, and composite fibers such as a core-sheath structure.
  • PE polyethylene
  • PP polypropylene
  • PET polyethylene terephthalate
  • fibers obtained by graft polymerization of PE and PP and composite fibers such as a core-sheath structure.
  • web forming is carried out by combining either a dry method (card method, spun bond method, meltblown method, air laid method, etc.) and a wet method, or a dry method and a wet method. It is also good.
  • a dry method card method, spun bond method, meltblown method, air laid method, etc.
  • a wet method dry method and a wet method. It is also good.
  • the method of bonding the web when producing the non-woven fabric used for the top sheet 2 include methods such as thermal bonding, needle punch, chemical bonding and the like, but are not limited to these methods.
  • a spunlace formed in a sheet shape by a water flow entanglement method may be used for the top sheet 2.
  • fibers of non-woven fabric used for the top sheet 2 composite fibers of core-sheath type, core-sheath eccentric type, or side-by-side type of different melting points of left and right components may be used.
  • hollow fibers, irregular fibers such as flat, Y-type and C-type, three-dimensional crimped fibers with latent crimp or apparent crimp, and split by physical load such as water flow, heat or embossing Fibers such as fibers may be mixed in the non-woven fabric used for the top sheet 2.
  • the fineness of the non-woven fabric used for the top sheet 2 is preferably 1.1 to 8.8 dtex.
  • hydrophobic synthetic fibers are used for the top sheet 2, in consideration of the liquid penetration and rewet of the top sheet 2, the hydrophilic agent, the water repellant, etc. are kneaded into the hydrophobic synthetic fibers, the hydrophilic agent or the water repellent
  • the hydrophobic synthetic fiber may be coated with a solution or the like.
  • the hydrophobic synthetic fiber may be rendered hydrophilic by corona treatment or plasma treatment.
  • the hydrophilic portion and the lipophilic portion coexist in the blood modifying agent application region 18 sparsely, and the hydrophilicity of the body fluid (for example, menstrual blood)
  • the sex component mainly plasma
  • the lipophilic component mainly blood cells
  • the non-woven fabric used for the top sheet 2 may contain an inorganic filler such as titanium oxide, barium sulfate and calcium carbonate.
  • an inorganic filler such as titanium oxide, barium sulfate and calcium carbonate.
  • At least the discharge port contact area 16 of the top sheet 2 is provided with a blood modifier application area 18 to which a blood modifier described later is applied.
  • the length in the longitudinal direction centering on the position where it abuts on the excretory opening of the wearer's body fluid is preferably 50 to 200 mm, more preferably 70 to 150 mm.
  • the length in the width direction is preferably 10 to 80 mm, more preferably 20 to 50 mm.
  • the top sheet 2 extends in the longitudinal direction (Y direction) at least in the discharge port contact area 16, and the projection 21 and the recess are arranged in a direction intersecting the longitudinal direction (Y direction), for example, in the width direction (X direction) Having 22.
  • the protrusion 21 and the recessed part 22 provided in the top sheet 2 are demonstrated in detail.
  • FIG. 3 is an enlarged perspective view of the protrusion 21 and the recess 22 of the top sheet 2.
  • the direction in which the protrusion 21 and the recess 22 extend is not limited to the longitudinal direction as long as it is a predetermined direction.
  • the top sheet 2 extends in the longitudinal direction (Y direction), and a plurality of protrusions 21 aligned in a direction intersecting the longitudinal direction (Y direction), for example, in the width direction (X direction) And the recess 22.
  • the shape of the cross section of the protrusion 21 is, for example, a substantially U shape.
  • the substantially U-shape includes, in addition to the U-shape, a shape that becomes a U-shape when it is deformed such as rounding corners or changing a straight line into a curve.
  • the substantially U-shape also includes V-shape, M-shape and trapezoid.
  • the shape of the cross section of the protrusion 21 may be ⁇ .
  • the thickness of the thickest portion of the projection 21 is preferably 0.3 to 15 mm, more preferably 0.5 to 5 mm.
  • the length in the width direction (X direction) of the projection is preferably 0.5 to 30 mm, more preferably 1.0 to 10 mm.
  • the distance (pitch) between the apexes in the width direction (X direction) of the adjacent protrusions is preferably 0.5 to 30 mm, more preferably 3 to 10 mm.
  • the thickness of the thinnest portion of the recess 22 is preferably 1 to 50%, more preferably 5 to 20% of the thickness of the thickest portion of the protrusion 21.
  • the length in the width direction (X direction) of the recess 22 is preferably 0.1 to 30 mm, more preferably 0.5 to 10 mm.
  • the fiber density of the central portion 23 of the projection 21 is preferably lower than the fiber density of the side 24 and / or the recess 22 of the projection 21.
  • the fiber density of the central portion 23 of the projection 21 and the recess 22 is 0.005 to 0.20 g / cm 3 , preferably 0.007 to 0.07 g / cm 3 .
  • the fiber density of each place of the top sheet can be measured, for example, as follows. A top sheet having a predetermined machine direction (MD) length, in which the projection 21 and the recess 22 are formed, is sampled.
  • MD machine direction
  • a microscope photograph or the like is used to take a photomicrograph of a cross section in the width direction (CD) of the top sheet, and the cross section of the central portion of the protrusion 21 in the top sheet, the cross section of the side portion of the protrusion, and the recess Cross sectional area is measured using an image processor.
  • the top sheet is cooled using liquid nitrogen or the like, and the central portion, the sides of the projection, and the recess of the cooled top sheet are respectively separated from the top sheet. Then, the weights of the central portion of the separated protrusion, the side portion of the protrusion, and the recess are measured.
  • the central part of the projection of the top sheet Fiber density of the side of the protrusion and fiber density of the recess can be calculated.
  • the magnitude relationship between the fiber density of the central portion 23 of the protrusion 21 and the fiber density of the side portion 24 and / or the recess 22 of the protrusion 21 is from the density relationship of fibers of the cross section of the top sheet. It can be judged.
  • the fiber density code 25 indicates the fibers of the top sheet 2.
  • a method of forming the protrusion 21 and the recess 22 in the top sheet 2 will be described.
  • a web 120 from which the topsheet 2 is made is placed on the mesh support member 130 and moved in the machine direction (MD).
  • the web 120 moves between the blowout unit 140 and the suction unit 150.
  • the blowout unit 140 jets the gas 141 onto the web 120, and the suction unit 150 sucks the gas 141 jetted from the blowout unit 140.
  • the gas 141 jetted from the blowout unit 140 scrapes the fibers of the web 120.
  • the groove 122 corresponding to the recess 22 of the top sheet 2 is formed in the web 120.
  • the fibers scraped off by the gas 141 jetted from the blowout portion 140 gather on both sides of the groove 122.
  • the protrusions 121 corresponding to the protrusions 21 of the top sheet 2 are formed on both sides of the groove 122.
  • the mesh support member 130 is a mesh support having breathability.
  • polyester, polyphenylene sulfide, nylon, resinous threads such as conductive monofilaments, or metallic threads such as stainless steel, copper, aluminum, etc. are woven by plain weave, twill weave, satin weave, double weave, spiral weave, etc.
  • the breathable net can be used as the mesh support member 130.
  • the blowout unit 140 includes a plurality of blowout ports (not shown) arranged in the width direction.
  • the blowout unit 140 can inject the plurality of gases 141 aligned in the width direction (CD) onto the web 120.
  • the gas 141 injected from the blowout part 140 is, for example, normal temperature or heated nitrogen, air and water vapor.
  • the gas 141 jetted from the blowoff unit 140 may contain liquid or solid particles.
  • the fiber density of the side surface of the protrusion 121 is increased. Further, since the groove 122 receives the gas 141 ejected from the blowout portion 140 and the web is compressed, the fiber density in the groove 122 becomes high. On the other hand, at the central portion of the protrusion 121, although the scraped fibers gather, they are not compressed by the gas 141 ejected from the blowout portion 140, so the fiber density at the central portion of the protrusion 121 becomes low. Thus, the fiber density of the central portion 23 of the projection 21 is lower than the fiber density of the side portion 24 and / or the recess 22 of the projection 21.
  • the back sheet 3 shown in FIGS. 1 and 2 prevents the body fluid absorbed by the absorber 4 from leaking out.
  • the back sheet 3 is made of a material that is impermeable to body fluid.
  • a hydrophobic non-woven fabric an impermeable plastic film such as polyethylene and polypropylene or a laminate sheet of non-woven fabric and an impermeable plastic film, or the like is used.
  • a spunbond-meltblown-spunbond (SMS) fibrous nonwoven fabric may be used as the back sheet 3 in which a highly water-resistant meltblown nonwoven fabric is sandwiched by strong spunbond nonwoven fabrics.
  • SMS spunbond-meltblown-spunbond
  • the absorber 4 absorbs and holds the body fluid. It is preferable that the absorber 4 is bulky, hard to lose its shape, and less in chemical stimulation.
  • a composite absorbent made of fluff pulp or air-laid non-woven fabric and super absorbent polymer (SAP) is used as the absorbent 4.
  • SAP super absorbent polymer
  • the composite absorber may be covered with a liquid permeable material such as a tissue.
  • artificial cellulose fibers such as chemical pulp, cellulose fibers, rayon and acetate may be used.
  • the basis weight of the absorbent fiber such as pulp in the composite absorbent is preferably 100 g / m 2 or more and 800 g / m 2 or less, and the mass ratio of the superabsorbent polymer in the composite absorbent is the absorbency
  • the fiber content is preferably 100% to 10% to 65%.
  • the basis weight of a liquid-permeable material such as a tissue covering the composite mixture is preferably 12 g / m 2 or more and 30 g / m 2 or less.
  • the air-laid non-woven fabric of the composite mixture for example, a non-woven fabric in which pulp and synthetic fibers are heat-sealed or a non-woven fabric in which pulp and synthetic fibers are fixed with a binder can be used.
  • the superabsorbent polymer of the composite absorbent has a three-dimensional network structure in which a water-soluble polymer is appropriately crosslinked.
  • the absorbent polymer absorbs 30 to 60 times as much water as the volume of absorbent polymer before absorbing water.
  • this absorbable polymer is essentially water insoluble.
  • the absorbent polymer does not release the water once absorbed, even if some pressure is applied.
  • this absorbent polymer for example, starch-based, acrylic acid-based or amino acid-based particulate or fibrous polymers are used.
  • the shape and structure of the absorber 4 can be changed as needed, but the total amount of absorption of the absorber 4 needs to correspond to the designed insertion amount as the absorbent article 1 and the desired application.
  • the size, absorption capacity and the like of the absorber 4 change depending on the application.
  • Absorber 4 is bonded to top sheet 2 using a hot melt adhesive. Thereby, it can suppress that the top sheet 2 peels from the absorber 4. As shown in FIG.
  • the side sheets 5 prevent the body fluid from leaking outward in the width direction of the absorbent article 1 through the surface and / or the inside of the top sheet 2.
  • the side sheets 5 preferably have hydrophobicity or water repellency.
  • a spunbonded nonwoven fabric or an SMS nonwoven fabric is used for the side sheet 5.
  • an air through non-woven fabric capable of reducing rubbing irritation to the skin for the side sheet 5.
  • the absorbent article 1 may not have the side sheet 5.
  • the wing portion 6 is provided on the absorbent article 1 in order to stably fix the absorbent article 1 to the undergarment.
  • the absorbent article 1 can be stably fixed to the undergarment by bending the wing portion 6 to the outer surface side of the undergarment and then sticking it to the crotch region of the undergarment through the adhesive portion 7.
  • region of underwear it can suppress that the main-body part 10 shifts
  • the adhesive part 7 of the absorbent article 1 shown in FIG. 2 fixes the absorbent article 1 to the crotch area of the undergarment.
  • an adhesive which forms the adhesion part 7 what is a styrene-type polymer, a tackifier, and a plasticizer as a main component, for example is used suitably.
  • the styrene-based polymer include styrene-ethylene-butylene-styrene block copolymer, styrene-butylene polymer, styrene-butylene-styrene block copolymer, and styrene-isobutylene-styrene copolymer. Or a blend of two or more polymers.
  • styrene-ethylene-butylene-styrene block copolymer is preferable in that the thermal stability is good.
  • tackifier and the plasticizer those which are solid at normal temperature can be preferably used, and as the tackifier, for example, C5 petroleum resin, C9 petroleum resin, dicyclopentadiene petroleum resin, rosin petroleum resin And polyterpene resins, terpene phenol resins, etc.
  • the plasticizer include, in addition to monomer plasticizers such as triflecil phosphate, dibutyl phthalate and dioctyl phthalate, polymer plasticizers such as vinyl polymers and polyesters.
  • the top sheet 2 and the absorbent body 4 have compressed grooves 8 extending from the top sheet 2 to the inside of the absorbent body 4 which are formed by being compressed in the thickness direction by embossing.
  • the squeeze groove 8 suppresses the diffusion of the body fluid discharged to the central portion of the absorbent article 1 (the portion in contact with the excretory port of the wearer's body fluid) in the width direction (X direction). Moreover, it can suppress that the top sheet 2 peels from the absorber 4 by this.
  • the squeeze groove 8 surrounds the central portion of the absorbent article 1 and has a continuous, substantially annular shape.
  • the pressing groove 8 surrounding the center part of the absorbent article 1 may be partially disconnected. That is, the pressing groove 8 may have a discontinuous and substantially annular shape.
  • the compression bonding of the top sheet 2 to the back sheet 3 by heat embossing forms the seal portion 9 on the edge portions on both sides in the longitudinal direction of the main body portion 10 and the edge portion on the width direction outer side of the wing portion 6 Ru.
  • the top sheet 2 can be prevented from peeling off from the back sheet 3.
  • the back sheet 3 and the side sheet 5 are joined at the seal portion 9 of the wing portion 6 by heat embossing. Thereby, the side sheet 5 can be prevented from coming off from the back sheet 3.
  • the blood modifying agent is about 0.00 to about 0.00 to about 100 g of water having a melting point of about 45 ° C. or less and an IOB of about 0.00 to about 0.60, and 100 g of water at 25 ° C. It has a water solubility of about 0.05 g.
  • IOB Inorganic Organic Balance
  • IOB value calculated by inorganic value / organic value.
  • the IOB is about 0.00 to about 0.60, preferably about 0.00 to about 0.50, and about 0.00 to about 0.40. More preferred is about 0 to about 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity to blood cells.
  • the "melting point” means the peak top temperature of an endothermic peak when changing from solid state to liquid state when measured at a temperature rising rate of 10 ° C./min in a differential scanning calorimeter.
  • the melting point can be measured, for example, using a DSC-60 type DSC measurement apparatus manufactured by Shimadzu Corporation.
  • the blood modifying agent may be liquid or solid at room temperature as long as it has a melting point of about 45 ° C. or less, ie, even if the melting point is about 25 ° C. or more, or less than about 25 ° C. It may well have a melting point such as, for example, about -5.degree. C., about -20.degree. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.
  • the vapor pressure of the blood modifying agent is preferably about 0.00 to about 0.01 Pa at 1 atm and 25 ° C., more preferably about 0.000 to about 0.001 Pa, and about 0 More preferably, it is from .0000 to about 0.0001 Pa.
  • the vapor pressure is preferably about 0.00 to about 0.01 Pa at 1 atm and 40 ° C., and about 0.000 to about 0.01 More preferably, it is about 0.001 Pa, and more preferably, about 0.0000 to about 0.0001 Pa. If the vapor pressure is high, it may be vaporized during storage, which may cause problems such as a decrease in the amount of blood modifying agent and an odor when worn.
  • the melting point of the blood modifying agent can be properly used depending on the weather, the length of wearing time, and the like. For example, in areas where the average temperature is less than about 10 ° C, menstrual blood may be excreted and then cooled by the ambient temperature by employing a blood modifying agent having a melting point of less than about 10 ° C. It is believed that blood modifying agents can stably modify blood.
  • the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or less. It is because it is hard to be affected by sweat, friction at the time of wearing, etc., and it is difficult for the blood modifying agent to move even when worn for a long time.
  • a water solubility of 0.00 to 0.05 g For a water solubility of 0.00 to 0.05 g, add a 0.05 g sample to 100 g deionized water at 25 ° C., allow to stand for 24 hours, and after 24 hours, lightly stir as needed, Then, it can be measured by visually evaluating whether the sample has dissolved.
  • dissolving includes cases where the sample is completely dissolved in deionized water to form a homogeneous mixture and cases where the sample is completely emulsified. "Complete” means that there is no clump of sample in deionized water.
  • the surface of the top sheet is coated with a surfactant for the purpose of changing blood surface tension and the like to rapidly absorb the blood.
  • the surfactant generally has high water solubility
  • the surfactant-coated top sheet is compatible with hydrophilic components (such as plasma) in the blood, rather the blood remains on the top sheet.
  • hydrophilic components such as plasma
  • solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.
  • the weight average molecular weight means a value in terms of polystyrene, which is determined by gel permeation chromatography (GPC).
  • GPC measurement conditions include the following. Model: High-performance liquid chromatogram Lachrom Elite manufactured by Hitachi High-Technologies Corporation Column: Showa Denko KK SHODEX KF-801, KF-803 and KF-804 Eluent: THF Flow rate: 1.0 mL / min Implanted volume: 100 ⁇ L Detection: RI (differential refractometer)
  • the weight average molecular weight described in the Example of this specification is measured based on the said conditions.
  • the above blood modifying agent is preferably selected from the following (i) to (iii), (I) Hydrocarbons, (Ii) from a carbonyl group (-CO-) and an oxy group (-O-) inserted between (ii-1) a hydrocarbon moiety and (ii-2) a C-C single bond of the above-mentioned hydrocarbon moiety
  • hydrocarbon means a compound consisting of carbon and hydrogen, and is a chain hydrocarbon, for example, paraffinic hydrocarbon (also referred to as alkane not containing double bond and triple bond) Olefinic hydrocarbons (containing one double bond, also called alkenes), acetylenic hydrocarbons (containing one triple bond, also called alkynes), and a group consisting of double bonds and triple bonds And hydrocarbons containing two or more bonds selected from, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
  • paraffinic hydrocarbon also referred to as alkane not containing double bond and triple bond
  • Olefinic hydrocarbons containing one double bond, also called alkenes
  • acetylenic hydrocarbons containing one triple bond, also called alkynes
  • hydrocarbons containing two or more bonds selected from, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
  • the hydrocarbon is preferably a chain hydrocarbon and an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a paraffin hydrocarbon, an olefin hydrocarbon and two double bonds. It is more preferable that it is the hydrocarbon (it does not contain a triple bond) which contains above, and it is still more preferable that it is a paraffinic hydrocarbon.
  • the chained hydrocarbons include straight chained hydrocarbons and branched chained hydrocarbons.
  • each oxy group (—O—) is not adjacent. Accordingly, the compounds (ii) and (iii) do not include compounds in which the oxy group is continuous (so-called peroxides).
  • At least one hydrogen atom of the hydrocarbon moiety is a hydroxyl group (-) rather than a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted with a carboxyl group (-COOH).
  • Compounds substituted with OH) are preferred.
  • Table 1 since the carboxyl group binds to metals and the like in blood, and the inorganic value greatly increases from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use This is because the IOB value may exceed about 0.60 and the affinity to blood cells may be reduced.
  • the above blood modifying agent comprises the following (i ') to (iii'), (I ') hydrocarbons, (Ii ') (ii'-1) a hydrocarbon moiety, and (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO) inserted between a C-C single bond of the above-mentioned hydrocarbon moiety -), A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-), and ether bond (-O-), and (iii ') (iii'-) 1) Carbonyl bond (-CO-), ester bond (-COO-), carbonate bond (-OCOO) inserted between the hydrocarbon moiety and the C-C single bond of the above-mentioned hydrocarbon moiety (iii'-2) A carboxyl group (-), and one or more, same or different bond selected from the group consisting of an ether bond (-O-) and (iii'
  • the blood modifying agent has about 1.8 or less carbonyl bonds (-CO-) and 2 or less ester bonds (-COO-) per 10 carbon atoms in the hydrocarbon moiety. About 1.5 or less carbonate bond (-OCOO-), about 6 or less ether bond (-O-), about 0.8 or less carboxyl group (-COOH), and / or hydroxyl group (-OH) Or a compound having about 1.2 or less).
  • the above blood modifying agent is any of the following (A) to (F), (A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the above chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety, (B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the above chain Ether with a compound having one hydroxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety, (C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) linear hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety
  • a compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the above chain Ester with a compound having one carboxyl group replacing hydrogen atoms in the cyclic hydrocarbon moiety (hereinafter sometimes referred to as “compound (A)”) has the above-mentioned IOB, melting point and water solubility And all hydroxyl groups may not be esterified.
  • (A1) a compound having a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atom of the above chain hydrocarbon portion (hereinafter sometimes referred to as “compound (A1)”)
  • chain hydrocarbon tetraols such as alkanetetraols such as pentaerythritol
  • chain hydrocarbon triols such as alkanetriols such as glycerin
  • chain hydrocarbon diols such as alkane diols such as Glycol is mentioned.
  • Examples of (A2) a compound having a chain hydrocarbon portion and one carboxyl group replacing the hydrogen atom of the chain hydrocarbon portion include, for example, And compounds in which one hydrogen atom on a hydrocarbon is substituted with one carboxyl group (—COOH), such as fatty acid.
  • Examples of the compound (A) include an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, an ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid, and (a 3 And esters of linear hydrocarbon diols and at least one fatty acid.
  • the ester of the above linear hydrocarbon tetraol and at least one fatty acid may be, for example, the following formula (1): Tetraester of pentaerythritol with fatty acid, the following formula (2): Triester of pentaerythritol with fatty acid, the following formula (3): A diester of pentaerythritol with fatty acid, the following formula (4): And monoesters of fatty acid with pentaerythritol. (Wherein, R 1 to R 4 are each a chain hydrocarbon)
  • esters of pentaerythritol and fatty acids have the above IOB, melting point and water solubility
  • saturated fatty acids such as C 2 to C 30 saturated fatty acids, for example, acetic acid (C 2 ) (C 2 represents a carbon number, R 1 C, R 2 C, R 3 C or R 4 C, which corresponds to the carbon number of R 2 C, hereinafter the same), propanoic acid (C 3 ), butanoic acid (C 4 ) and isomers thereof, for example, 2-methylpropanoic acid (C 4) ), pentanoic acid (C 5) and isomers thereof such as 2-methylbutanoic acid (C 5), 2,2-dimethyl propanoic acid (C 5), hexanoic acid (C 6), heptanoic acid (C 7) Oct
  • the fatty acids can also be unsaturated fatty acids.
  • unsaturated fatty acids include C 3 -C 20 unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C 4 ), myristoleic acid (C 14 ), palmitoleic acid (C 16 ), Oleic acid (C 18 ), elaidic acid (C 18 ), vacenic acid (C 18 ), gadeuric acid (C 20 ), eicosenic acid (C 20 ), etc., diunsaturated fatty acids such as linoleic acid (C 18 ), Eicosadienoic acid (C 20 ) and the like, triunsaturated fatty acids such as linolenic acid, for example ⁇ -linolenic acid (C 18 ) and ⁇ -linolenic acid (C 18 ), pinolenic acid (C 18 ), eleostearic acid, For example, ⁇ -eleostearic acid (C 18
  • the ester of pentaerythritol and fatty acid is an ester of pentaerythritol and fatty acid derived from saturated fatty acid, that is, an ester of pentaerythritol and saturated fatty acid, in consideration of the possibility of modification by oxidation etc. preferable.
  • the ester of pentaerythritol and a fatty acid in order to make IOB small and make it more hydrophobic, it is preferable to be a diester, a triester or a tetraester, and a triester or a tetraester is more preferable. And tetra-esters are more preferred.
  • the total carbon number of fatty acids constituting the tetraester of pentaerythritol and fatty acid that is, in the above formula (1), R 1 C, R 2 C, R 3 C and When the total number of carbons in the R 4 C portion is 15, the IOB is 0.60. Therefore, in the case of tetraester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbons is about 15 or more.
  • Examples of the tetraester of pentaerythritol and fatty acid include pentaerythritol, hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), for example, 2-ethylhexanoic acid (C 8 ), These include tetraesters with nonanoic acid (C 9 ), decanoic acid (C 10 ) and / or dodecanoic acid (C 12 ).
  • the total carbon number of the fatty acid constituting the triester of pentaerythritol and fatty acid that is, the R 1 C, R 2 C and R 3 C moieties in the above formula (2)
  • the IOB is 0.58 when the sum of the carbon numbers of these is 19. Therefore, in the case of the triester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 19 or more.
  • the total carbon number of fatty acids constituting the diester of pentaerythritol and fatty acid that is, the total carbon number of R 1 C and R 2 C in the above formula (3) is In the case of 22, the IOB is 0.59. Accordingly, in the diester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 22 or more.
  • esters of pentaerythritol and fatty acid examples include Unistar H-408 BRS, H-2408 BRS-22 (mixed product), etc. (all manufactured by NOF Corporation).
  • the ester of the above linear hydrocarbon triol and at least one fatty acid may be, for example, the following formula (5): Triester of glycerin and fatty acid, the following formula (6): A diester of glycerin and a fatty acid, and the following formula (7): (Wherein, each of R 5 to R 7 is a chain hydrocarbon) And monoesters of glycerin and fatty acids.
  • fatty acids (R 5 COOH, R 6 COOH and R 7 COOH) constituting the ester of glycerin and fatty acid if the ester of glycerin and fatty acid satisfies the requirements of the above IOB, melting point and water solubility
  • the fatty acids listed in the “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid” are not particularly limited, and examples thereof include saturated fatty acids and unsaturated fatty acids, which are modified by oxidation etc. In consideration of the possibility of doing so, an ester of glycerin and a fatty acid derived from a saturated fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferable.
  • ester of glycerol and a fatty acid in order to make IOB small and to make it more hydrophobic, it is preferable that it is diester or triester, and it is more preferable that it is triester.
  • triester of glycerin and fatty acid is also referred to as triglyceride, for example, triester of glycerin and octanoic acid (C 8 ), triester of glycerin and decanoic acid (C 10 ), glycerin and dodecanoic acid (C 12 And triesters of glycerin with two or three fatty acids, and mixtures thereof.
  • Examples of the triester of the above glycerin and two or more fatty acids include triester of glycerin and octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin, octanoic acid (C 8 ), decane Acid (C 10 ) and triester with dodecanoic acid (C 12 ), glycerin and octanoic acid (C 8 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), tetradecanoic acid (C 14 ), hexadecanoic acid Examples thereof include triesters with (C 16 ) and octadecanoic acid (C 18 ).
  • the total carbon number of fatty acids constituting the triester of glycerin and fatty acid ie, R 5 C in the formula (5)
  • the sum of the carbon numbers of the R 6 C and R 7 C moieties is about 40 or less.
  • the total carbon number of fatty acids constituting the triester of glycerin and fatty acid that is, in the formula (5), the R 5 C, R 6 C and R 7 C moieties
  • the IOB is 0.60. Therefore, in the above-mentioned triesters of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 12 or more.
  • the above-mentioned triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute the human body, and thus is preferable from the viewpoint of safety.
  • tricotic oil fatty acid glyceride NA36
  • PANACET 800 PANACET 800B
  • PANACET 810S avian C2L oil fatty acid glyceride and triCL oil fatty acid glyceride (manufactured by NOF CORPORATION) Etc.).
  • the above-mentioned diester of glycerin and fatty acid is also referred to as diglyceride, for example, a diester of glycerin and decanoic acid (C 10 ), a diester of glycerin and dodecanoic acid (C 12 ), and glycerin and hexadecanoic acid (C 16 ) Included are diesters and diesters of glycerin with two fatty acids, and mixtures thereof.
  • the total carbon number of fatty acids constituting the diester of glycerin and fatty acid ie, the case where the total carbon number of R 5 C and R 6 C moieties in the formula (6) is 16
  • the IOB is 0.58. Therefore, in the case of the diester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 16 or more.
  • the monoester of glycerin and fatty acid is also referred to as monoglyceride, and examples thereof include icosanoic acid (C 20 ) monoester of glycerin, docosanoic acid (C 22 ) monoester of glycerin and the like.
  • the carbon number of fatty acid constituting the monoester of glycerin and fatty acid that is, in the formula (7), the IOB is 0.59 when the carbon number of the R 5 C portion is 19 It becomes. Therefore, in the monoester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the fatty acid is about 19 or more.
  • esters of the above linear hydrocarbon diol and at least one fatty acid include C 2 to C 6 linear hydrocarbon diols, such as C 2 to C 6 glycols, such as ethylene glycol, propylene glycol, butylene And mono- or diesters of glycol, pentylene glycol or hexylene glycol with fatty acids.
  • ester of the above linear hydrocarbon diol and at least one fatty acid for example, the following formula (8): R 8 COOC k H 2k OCOR 9 (8) (Wherein k is an integer of 2 to 6 and R 8 and R 9 are each a chain hydrocarbon) A diester of a C 2 -C 6 glycol with a fatty acid, and the following formula (9): R 8 COOC k H 2k OH (9) (Wherein k is an integer of 2 to 6 and R 8 is a chain hydrocarbon) And monoesters of fatty acid with C 2 -C 6 glycol.
  • ester of C 2 to C 6 glycol and fatty acid as the fatty acid to be esterified (corresponding to R 8 COOH and R 9 COOH in the formula (8) and the formula (9)), C 2 to C 6 glycol
  • ester of fatty acid with the fatty acid provided that it satisfies the requirements of the above IOB, melting point and water solubility, for example, "ester of (a 1 ) chain hydrocarbon tetraol with at least one fatty acid"
  • the ester of a C 2 ⁇ C 6 glycols and fatty acid in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C 2 ⁇ C 6 glycols and fatty acid, Nachi Suwa, C 2 It is preferably an ester of a -C 6 glycol and a saturated fatty acid.
  • ester of C 2 -C 6 glycol and fatty acid an ester of glycol and fatty acid derived from glycol having a large number of carbon atoms, for example, butylene glycol, in order to make IOB small and make it more hydrophobic. It is preferable that it is an ester of a glycol derived from pentylene glycol or hexylene glycol and a fatty acid.
  • ester of C 2 -C 6 glycol and fatty acid a diester is preferable in order to make IOB small and to make it more hydrophobic.
  • examples of commercial products of the ester of C 2 -C 6 glycol and fatty acid include Commol BL, Commol BS (manufactured by NOF Corporation) and the like.
  • (B) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and Ether with compound having one hydroxyl group replacing hydrogen atom of linear hydrocarbon moiety
  • (B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the above chain Ether with a compound having one hydroxyl group replacing hydrogen atoms in the cyclic hydrocarbon moiety (hereinafter sometimes referred to as “compound (B)”) has the above-mentioned IOB, melting point and water solubility And all hydroxyl groups may not be etherified.
  • Examples of the compound having (B1) a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atoms of the above chain hydrocarbon portion are listed as the compound (A1) in the “compound (A)”.
  • Examples of (B2) a compound having a linear hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the linear hydrocarbon moiety include, for example, A compound in which one hydrogen atom of hydrocarbon is substituted with one hydroxyl group (—OH), for example, aliphatic monohydric alcohol such as saturated aliphatic monohydric alcohol and unsaturated aliphatic monohydric alcohol Can be mentioned.
  • saturated aliphatic monohydric alcohol for example, a C 1 to C 20 saturated aliphatic monohydric alcohol, for example, methyl alcohol (C 1 ) (C 1 represents a carbon number, the same applies hereinafter), ethyl alcohol C 2 ), propyl alcohol (C 3 ) and its isomers, such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and its isomers, such as sec-butyl alcohol (C 4 ) and tert-butyl alcohol (C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof, such as 2-ethylhexyl alcohol (C 8 ), nonyl alcohol (C 9 ), decyl alcohol (C 10 ), dodecyl alcohol (C 12 ), tetradecyl al Call (C 14), hexadect
  • an ether of (b 1 ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol for example, monoether, diether, triether and tetraether, preferably diether, triether Ethers and tetraethers, more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (b 2 ) chain hydrocarbon triols and at least one aliphatic monohydric alcohol, such as monoethers, diethers and the like triether, preferably diethers and triethers and more preferably tri-ether, and (b 3) a chain hydrocarbon diol and at least one aliphatic monohydric ether alcohols, for example, mono- and diethers and, Mashiku diethers.
  • Examples of the ether of the above linear hydrocarbon tetraol and at least one aliphatic monohydric alcohol include the following formulas (10) to (13): (Wherein, each of R 10 to R 13 is a chain hydrocarbon). And tetraethers of pentaerythritol and aliphatic monohydric alcohols, triethers, diethers and monoethers.
  • Examples of the ether of the above linear hydrocarbon triol and at least one aliphatic monohydric alcohol include the following formulas (14) to (16): (Wherein, R 14 to R 16 are each a chain hydrocarbon). And triethers of glycerol and aliphatic monohydric alcohols, diethers and monoethers.
  • R 17 OC n H 2n OR 18 (Wherein n is an integer of 2 to 6 and R 17 and R 18 are each a chain hydrocarbon) Diethers of C 2 -C 6 glycols and aliphatic monohydric alcohols, and the following formula (18): R 17 OC n H 2n OH (18) (Wherein n is an integer of 2 to 6 and R 17 is a chain hydrocarbon) And monoethers of C 2 -C 6 glycols and aliphatic monohydric alcohols.
  • the total carbon number of aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (10)
  • the IOB is 0.44. Therefore, in the above tetraether of pentaerythritol and aliphatic monohydric alcohol, IOB is required to be about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 4 or more. Fulfill.
  • the total carbon number of aliphatic monohydric alcohol constituting triether of pentaerythritol and aliphatic monohydric alcohol ie, in the above formula (11)
  • the IOB is 0.57. Therefore, in the above triether of pentaerythritol and aliphatic monohydric alcohol, IOB is required to be about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 9 or more. Fulfill.
  • the total carbon number of aliphatic monohydric alcohols constituting the diether of pentaerythritol and aliphatic monohydric alcohol that is, R 10 in the above formula (12)
  • the IOB is 0.60 when the sum of the carbon numbers of the and R 11 moieties is 15. Therefore, in the diether of pentaerythritol and aliphatic monohydric alcohol, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 15 or more. .
  • the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol that is, R 10 in the above formula (13)
  • the IOB is 0.59. Therefore, in the monoether of pentaerythritol and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the aliphatic monohydric alcohol is about 22 or more.
  • the total carbon number of aliphatic monohydric alcohol constituting triether of glycerin and aliphatic monohydric alcohol that is, R in the formula (14)
  • the IOB is 0.50. Therefore, in the above triether of glycerin and aliphatic monohydric alcohol, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 3 or more. .
  • the total carbon number of aliphatic monohydric alcohols constituting the diether of glycerin and an aliphatic monohydric alcohol that is, in the formula (15), R 14 and R 15
  • the IOB is 0.58. Therefore, in the diether of glycerin and an aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of the aliphatic monohydric alcohol is about 9 or more.
  • the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol that is, the carbon of R 14 in the formula (16)
  • the IOB is 0.58. Therefore, in the monoether of glycerin and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the aliphatic monohydric alcohol is about 16 or more.
  • the compound (B) can be produced by dehydration condensation of the compound (B1) and the compound (B2) in the presence of an acid catalyst.
  • compound C1 a linear hydrocarbon moiety and a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety
  • compound C1 may be, for example, a linear hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a linear hydrocarbon dicarboxylic acid, such as an alkane dicarboxylic acid, such as ethanedioic acid.
  • a linear hydrocarbon hydroxy acid having 2 to 4 carboxyl groups for example, a linear chain having 2 to 4 carboxyl groups, such as malic acid, tartaric acid, citric acid, isocitric acid, etc.
  • Hydrocarbon alkoxy acids such as O-acetyl citric acid, and linear hydrocarbon oxo acids having 2 to 4 carboxyl groups are included.
  • Examples of the compound having a (C2) linear hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the linear hydrocarbon moiety include those listed in the “compound (B)”, for example, Aliphatic monohydric alcohols are mentioned.
  • an ester of a linear hydrocarbon tetracarboxylic acid having 4 carboxyl groups (c 1 ), a hydroxy acid, an alkoxy acid or an oxo acid, and at least one aliphatic monohydric alcohol for example, Mono-, di-, tri- and tetra-esters, preferably diesters, tri- and tetra-esters, more preferably tri- and tetra-esters, and still more preferably tetra-esters, chained with 3 (c 2 ) carboxyl groups
  • Esters of hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxo acids with at least one aliphatic monohydric alcohol such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters Ester
  • aliphatic monohydric alcohol constituting the above ether corresponding to R 19 OH and R 20 OH in the formula (19)
  • the above ether satisfies the requirements of the above IOB, melting point and water solubility It is not particularly limited, and examples thereof include aliphatic monohydric alcohols listed in the “compound (B)” section.
  • the total carbon number of the aliphatic monohydric alcohol constituting the ether that is, the carbon number of the R 19 and R 20 moieties in the above formula (19) Since the IOB is 0.50 when the sum of the two is 2, the requirement of the above IOB is satisfied if the total carbon number is about 2 or more. However, when the total carbon number is about 6, the water solubility is as high as about 2 g, and there is also a problem from the viewpoint of the vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more.
  • dialkyl ketone [(D 2 ) dialkyl ketone]
  • dialkyl ketone following Formula (20): R 21 COR 22 (20) (Wherein, each of R 21 and R 22 is an alkyl group) And compounds having the formula:
  • the total carbon number is preferably about 8 or more. Also, in consideration of the vapor pressure, the carbon number is preferably about 10 or more, and preferably about 12 or more.
  • the melting point is about ⁇ 50 ° C.
  • the vapor pressure is about 230 Pa at 20 ° C.
  • the above-mentioned dialkyl ketone is commercially available and can be obtained by a known method, for example, oxidation of a secondary alcohol with chromic acid or the like.
  • Examples of the fatty acid (corresponding to R 23 COOH in the formula (21)) constituting the above-mentioned ester are listed, for example, in “ester of (a 1 ) chain hydrocarbon tetraol with at least one fatty acid”.
  • a fatty acid that is, a saturated fatty acid or an unsaturated fatty acid is mentioned, and considering the possibility of modification by oxidation etc., a saturated fatty acid is preferred.
  • the aliphatic monohydric alcohol (corresponding to R 24 OH in the formula (21)) constituting the above-mentioned ester include, for example, aliphatic monohydric alcohols listed in the “compound (B)” section.
  • the sum of carbon number of fatty acid and aliphatic monohydric alcohol that is, the sum of carbon number of R 23 C and R 24 in the formula (21) is 5
  • the IOB is 0.60
  • the requirements of the above IOB are satisfied when the total carbon number of the R 23 C and R 24 moieties is about 5 or more.
  • the vapor pressure is as high as 2,000 Pa or more. Therefore, in consideration of the vapor pressure, the total carbon number is preferably about 12 or more. If the total carbon number is about 11 or more, the water solubility can satisfy the requirement of about 0.00 to about 0.05 g.
  • esters of the above fatty acids with aliphatic monohydric alcohols include, for example, esters of dodecanoic acid (C 12 ), dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 )
  • esters of fatty acids and aliphatic monohydric alcohols include Electol WE 20 and Electol WE 40 (all manufactured by NOF Corporation).
  • the total carbon number of R 25 and R 26 is preferably about 7 or more, and more preferably about 9 or more.
  • the above dialkyl carbonate is commercially available, and can be synthesized by the reaction of phosgene with alcohol, the reaction of formic acid chloride ester with alcohol or alcoholate, and the reaction of silver carbonate with alkyl iodide.
  • Examples of the above-mentioned polyoxy C 2 -C 6 alkylene glycol or ester or ether thereof include (e 1 ) polyoxy C 2 -C 6 alkylene glycol, (e 2 ) polyoxy C An ester of a 2 to C 6 alkylene glycol with at least one fatty acid, an ether of (e 3 ) polyoxy C 2 to C 6 alkylene glycol and at least one aliphatic monohydric alcohol, (e 4 ) polyoxy C 2 to C 6 An ester of an alkylene glycol with a linear hydrocarbon tetracarboxylic acid, a linear hydrocarbon tricarboxylic acid, or a linear hydrocarbon dicarboxylic acid, and (e 5 ) polyoxy C 2 -C 6 alkylene glycol, with a linear hydrocarbon tetra And ethers with linear hydro
  • oxy C 2 ⁇ C 6 alkylene backbone from the viewpoint of lowering the polyoxy C 2 ⁇ C 6 IOB of alkylene glycols, polyoxypropylene skeleton, oxybutylene skeleton, it is oxypentylene skeleton, or an oxy hexylene skeleton preferably More preferably, they are an oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton.
  • the above polyoxy C 2 -C 6 alkylene glycol has the following formula (23): HO- (C m H 2m O) n -H (23) (In the formula, m is an integer of 2 to 6) Can be represented by
  • homopolymers of formula (23) may include homopolymers of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. From the above, in the formula (23), m is about 3 to about 6, and more preferably about 4 to about 6, and n is 2 or more.
  • n the poly C 2 -C 6 alkylene glycol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. It is a value that has a water solubility of about 0.00 to about 0.05 g.
  • the weight average molecular weight of the polyoxy C 2 -C 6 alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and more preferably It is in the range of about 250 to about 5,000.
  • the weight average molecular weight of the poly C 3 alkylene glycol, ie, polypropylene glycol is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8 And more preferably in the range of about 4,000 to about 5,000.
  • the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirements, and the larger the weight average molecular weight, the more the absorber transfer rate and the top sheet whiteness tend to be improved.
  • Examples of commercial products of polyoxy C 2 ⁇ C 6 alkylene glycol e.g., UNIOL (TM) D-1000, D-1200 , D-2000, D-3000, D-4000, PB-500, PB-700, PB -1000 and PB-2000 (manufactured by NOF Corporation).
  • UNIOL TM
  • D-1000, D-1200 , D-2000, D-3000, D-4000, PB-500, PB-700, PB -1000 and PB-2000 manufactured by NOF Corporation.
  • ester of (e 2 ) polyoxy C 2 -C 6 alkylene glycol with at least one fatty acid is the OH terminal of the polyoxy C 2 to C 6 alkylene glycol described in the section “(e 1 ) polyoxy C 2 to C 6 alkylene glycol”.
  • fatty acids ie, monoesters and diesters.
  • the fatty acid to be esterified is, for example, listed in “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”.
  • Fatty acids that is, saturated fatty acids or unsaturated fatty acids, and in view of the possibility of modification by oxidation etc., saturated fatty acids are preferred.
  • Examples of commercially available esters of the polyoxy C 2 -C 6 alkylene glycol and fatty acid include Wilbright cp 9 (manufactured by NOF Corporation).
  • aliphatic monohydric alcohols to be etherified in the ether of polyoxy C 2 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol include, for example, aliphatics listed in the “compound (B)” section. Monohydric alcohol is mentioned.
  • esters of the above polyoxy C 2 -C 6 alkylene glycol with chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid are commercially available, and chain hydrocarbon tetracarbons are also commercially available. It can be produced by polycondensation of C 2 -C 6 alkylene glycol with an acid, linear hydrocarbon tricarboxylic acid or linear hydrocarbon dicarboxylic acid under known conditions.
  • chain hydrocarbon tetraol to be etherified the chain hydrocarbon triol, and the chain hydrocarbon diol, those described in the “compound (A)” section, for example, pentaerythritol, glycerin and glycol Can be mentioned.
  • ethers of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol are, for example, UnilobeTM 5TP-300 KB, and Uniol (trademark) TG-3000 and TG-4000 (made by NOF Corporation) can be mentioned.
  • Unilube (TM) 5TP-300KB is a compound obtained by polycondensation of 65 moles of propylene glycol and 5 moles of ethylene glycol with 1 mole of pentaerythritol, and its IOB is 0.39, and the melting point is less than 45 ° C. And the water solubility was less than 0.05 g.
  • Uniol (TM) TG-3000 is a compound obtained by polycondensing 50 moles of propylene glycol with 1 mole of glycerin, its IOB is 0.42, its melting point is less than 45 ° C, and its water solubility is 0.05 g And the weight average molecular weight was about 3,000.
  • Uniol (TM) TG-4000 is a compound obtained by polycondensing 70 moles of propylene glycol with 1 mole of glycerin, its IOB is 0.40, melting point is less than 45 ° C., and water solubility is 0.05 g And the weight average molecular weight was about 4,000.
  • the ether of the polyoxy C 2 -C 6 alkylene glycol and the chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol is also a chain hydrocarbon tetraol, chain hydrocarbon triol or It can be produced by adding a C 2 -C 6 alkylene oxide to a linear hydrocarbon diol under known conditions.
  • the chain hydrocarbon has an IOB of 0.00 and an aqueous solubility of almost 0 g because the inorganic value is 0, and the blood has a melting point of about 45 ° C. or less. It may be included in the modifier.
  • Examples of the chain hydrocarbon include (f 1 ) chain alkanes such as straight chain alkanes and branched chain alkanes, and in the case of straight chain alkanes, for example, the melting point is about 45 ° C. or less In general, those containing 22 or less carbon atoms are included. Also, in consideration of the vapor pressure, those having 13 or more carbon atoms are generally included.
  • the blood modifying agent has been found to at least have the effect of reducing blood viscosity and surface tension. Since the menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall as compared with normal blood, they act to connect the blood cells to each other, and the blood cells are in a continuous state. Cheap. Therefore, the menstrual blood to be absorbed by the absorbent article tends to have a high viscosity, and when the top sheet is a non-woven fabric or a woven fabric, menstrual blood tends to be clogged between fibers, and the wearer feels sticky. And it spreads and leaks on the surface of the top sheet.
  • a blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily enters between blood cells, thereby stabilizing the blood cells and making it difficult for the blood cells to form a continuous structure. It is thought that can be done. It is considered that the absorber makes it easy to absorb menstrual blood by stabilizing the blood cells and making the blood cells less likely to form a continuous structure.
  • the so-called SAP when menstrual blood is absorbed, blood cells that have undergone continuous change cover the SAP surface, making it difficult for the SAP to exhibit its absorption performance.
  • SAP By stabilizing blood cells, it is considered that SAP can more easily exhibit absorption performance.
  • the blood modifying agent having high affinity for red blood cells protects the red blood cell membrane, so that the red blood cells are less likely to be destroyed.
  • the coating weight of the blood modifying agent on the top sheet 2 is preferably 1 to 30 g / m 2 , more preferably 3 to 10 g / m 2 .
  • the coating weight of the blood modifying agent is smaller than 1 g / m 2 , it may be difficult to stably apply the blood modifying agent to the top sheet 2, and the coating weight of the blood modifying agent is 30 g / m. If it is larger than m 2 , the top sheet 2 may be slimy.
  • the blood modifier is heated to a desired temperature and then applied to the top sheet 2 using a contact coater such as a slot coater or a noncontact coater such as a spray coater, a curtain coater, or a spiral coater. From the point of being able to uniformly disperse the droplet-like blood modifying agent in the blood modifying agent application region 8 and from the point of not damaging the top sheet 2, the non-contact coater is used to use the non-contact coater It is preferable to apply to 2.
  • a contact coater such as a slot coater or a noncontact coater such as a spray coater, a curtain coater, or a spiral coater.
  • the blood modifying agent may be applied to the non-woven fabric when making the non-woven fabric for the top sheet.
  • a blood modifying agent may be applied to the top sheet 2 in the manufacturing process of the absorbent article 1.
  • the blood modifying agent is used as the top sheet in a process close to the completion of the absorbent article 1. It is preferable to apply to 2.
  • a blood modifying agent may be applied to the top sheet 2 immediately before the step of packaging the absorbent article 1.
  • FIG. 5 is a view for explaining the absorbent article 1 in which the wing portion 6 is folded for packaging.
  • a pair of wing part 6 is folded inside in the width direction.
  • the adhesive portion 7 is covered by a release sheet 33.
  • the release sheet 33 is not particularly limited as long as it is a sheet that can be released to the adhesive of the adhesive unit 7.
  • the release sheet 33 for example, one obtained by applying a release agent to a substrate can be used.
  • the substrate to which the release agent is applied include films of polypropylene, low density polyethylene, polyvinyl alcohol and the like, nonwoven fabrics, paper and the like, and examples of the release agent include silicones, fluorines and isocyanates.
  • FIG. 5 when the absorbent article 1 is packaged, the absorbent article 1 in which the wing portion 6 is folded is placed on the packaging material 31.
  • the packaging material 31 is, for example, a non-woven fabric or a resin film.
  • a fastening tape 32 is provided at an end of the packaging material 31 in the longitudinal direction.
  • the absorbent article 1 disposed on the packaging material 31 is folded along with the packaging material 31 in the longitudinal direction (Y direction) along the lines BB and CC.
  • the fastening tape 32 is then used to maintain the absorbent article 1 in a folded state.
  • both sides 31 a in the width direction of the packaging material 31 folded together with the absorbent article 1 are joined by heat embossing.
  • FIG. 6 is a perspective view of a package 30 including an absorbent article.
  • FIG. 7 is a schematic cross-sectional view showing a cross section taken along line DD of FIG.
  • the side sheet 5 in the wing 6 when the wing 6 is folded contacts the blood modifier application region 18 (see FIG. 1) of the top sheet 2. Since the blood modifying agent application region 18 is coated with the blood modifying agent, the top sheet 2 in the wing portion 6 comes in contact with the blood modifying agent. However, the contact area between the side sheet 5 in the wing portion 6 and the blood modifying agent application region 18 of the top sheet 2 is reduced by the protrusion 21 of the top sheet 2.
  • the fiber density of the central portion 23 of the projection 21 is lower than the fiber density of the side 24 and / or the recess 22 of the projection 21 (see FIG. 3).
  • the blood modifying agent applied to the blood modifying agent application region 18 of the top sheet 2 tends to be collected at a place where the fiber density of the top sheet 2 is high.
  • the fiber density of the central portion 23 of the protrusion 21 in contact with the wing portion 6 is lower than that of the side portion of the protrusion 21 and the recess 22. Agents do not collect much.
  • the amount of blood modifying agent transferred to the wing portion 6 is further reduced by lowering the fiber density of the central portion 23 of the projection 21 as compared with the fiber density of the side portion 24 of the projection 21 and / or the recess 22 It can be done.
  • the absorbent article 1 can be modified as follows.
  • the opening 26A may be formed in the recess 22A of the top sheet 2A.
  • FIG. 8A is an enlarged perspective view of a protrusion, a recess, and an opening formed on the top sheet 2.
  • FIG. 8B is an enlarged view of the protrusion, the recess, and the opening formed on the top sheet 2.
  • the fiber density of the side surface of the opening 26A is preferably higher than the fiber density of the central portion 23A of the protrusion 21A.
  • a large amount of blood modifying agent applied to the top sheet gathers around the opening 26A formed in the recess 22A, so that the central portion 23 of the protrusion 21 in contact with the wing 6 is modified with blood. Many agents do not collect. Therefore, by making the fiber density of the side surface of the opening 26A higher than the fiber density of the central portion 23A of the projection 21A, the amount of blood modifying agent transferred to the wing 6 when the wing 6 is folded is reduced. It can be done. As a result, the blood modifying agent applied to the top sheet 2A penetrates the wing portion 6 to suppress peeling of the side sheet 5 constituting the wing portion 6 from the back sheet 3.
  • the top sheet 2A is provided by providing the mesh support member 130 with a plurality of elongated members 160 extending in the width direction (CD) and aligned in the machine direction (MD) and not having air permeability.
  • the opening 26A can be formed in the recess 22A. Since the gas 141 jetted from the blowout part 140 passes through the mesh-like support member 130 in the portion where the elongated member 160 of the mesh-like support member 130 is not provided, the fibers of the web 120 can be formed to the extent that the groove 122 can be formed in the web 120 Are separated.
  • the gas 141 injected from the blowout portion 140 does not pass through the reticular support member 130 and stops at the elongated member 160.
  • the openings can be formed in the web 120, they are scraped off strongly.
  • the opening 26A is formed in the recess 22A of the top sheet 2A. Since scraped fibers are densely packed on the side face of the opening 26A, the fiber density on the side face of the opening 26A is high.
  • FIG. 10 is a schematic perspective view of a modification of the top sheet.
  • the opening 26C may be formed in the recess 22C of the top sheet 2C in which the protrusion 21C and the recess 22C are formed by bending the nonwoven fabric in a wave shape.
  • FIG.11 (a) is a schematic perspective view of the modification of a top sheet
  • FIG.11 (b) is a schematic plan view of the modification of a top sheet.
  • a projection roll having a plurality of projections in a needle shape, a cylindrical shape, and a conical shape on the outer peripheral surface
  • an anvil roll having a recess on the outer peripheral surface that engages with the projection at a position corresponding to the projections of the projection roll.
  • a top sheet having the opening 26C formed in the recess 22C can be manufactured by passing the non-woven fabric folded in a wave shape between them.
  • the openings 26C are formed by the projections of the projection rolls penetrating the non-woven fabric, so that pressure is applied to the side surfaces of the openings 26C when the openings 26C are formed. Therefore, the fiber density of the side surface of the opening 26C is higher than the fiber density of the central portion 23C of the protrusion 21C. Therefore, since the blood modifying agent applied to the top sheet 2C gathers on the side surface of the opening 26C of the recess 22C of the top sheet 2C, the amount of the blood modifying agent transferred to the wing 6 when the wing 6 is folded. Can be reduced. Thereby, when the blood modifier applied to top sheet 2C penetrates to wing part 6, it can control that side sheet 5 which constitutes wing part 6 exfoliates from back sheet 3.
  • FIG. 12 is a schematic cross-sectional view of an absorbent article 1D corresponding to the line AA of FIG.
  • the compression part 8D formed in the absorbent article 1D may be a linear compression part or a point-like compression part. Compression part 8D can be formed in absorptive article 1D, for example by embossing.
  • the compression section 8D is formed by compressing the top sheet 2D and the absorber 4D in the thickness direction, the density of the top sheet 2D and the absorber 4D near the bottom of the compression section 8D is high. For this reason, the blood modifying agent applied to the top sheet 2D gathers toward the bottom of the compression unit 8D. Therefore, when the wing 6 is folded, the blood modifying agent application region 18 of the top sheet 2 starts from the wing 6 The amount of blood modifying agent to be transferred to can be further reduced. Thereby, when the blood modifier applied to top sheet 2D penetrates into wing part 6, it can control that side sheet 5 which constitutes wing part 6 exfoliates from back sheet 3.
  • the compression section 8D When forming the compression section 8D, if the top sheet 2D of the compression section 8D is formed into a film, the blood modifying agent does not permeate into the top sheet 2D, so the top sheet 2D in the compression section 8D is not formed into a film Is preferred.
  • the projection formed on the blood modifier application area 18 of the top sheet 2 is the above-mentioned.
  • the projections of may be provided in the blood modifier application region 18 of the top sheet 2.
  • protrusions extending in the longitudinal direction (Y direction) or the width direction (X direction) in a wavelike form may be provided in the blood modifier application region 18 of the top sheet 2.
  • a protrusion having a shape of a cylinder, a prism, a hemisphere, or the like may be provided in the blood modifying agent application region 18 of the top sheet 2.
  • a protrusion may be formed on the side sheet 5.
  • the side sheet 5E may be provided with the longitudinally extending protrusion 51 formed by bending in a wave shape.
  • FIG. 13 is a schematic cross-sectional view of the absorbent article 1E corresponding to the line AA of FIG. If it can do, the protrusion formed in the blood modifier application area 18 of the top sheet 2 is not limited to the above-mentioned protrusion. In addition, you may provide the protrusion extended in the width direction in a side seat.
  • the side sheet with the protrusion extended in a longitudinal direction or the width direction in a wavelike form.
  • a protrusion having a shape of a cylinder, a prism, a hemisphere, or the like may be provided on the side sheet.
  • the composition to be applied to the top sheet is not limited to the blood modifier as long as it is a predetermined composition.
  • a lotion for preventing rough skin may be applied to the top sheet.
  • the blood modifying agent since the blood modifying agent has a mechanism to lower the viscosity and surface tension of the blood, the body fluid is transferred to the absorber 4 without remaining on the top sheet 2 by the blood modifying layer 24 and absorbed. 4 can be absorbed.
  • the sanitary napkin comprises a top sheet formed of an air through non-woven fabric (composite fiber of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent, and a composite of air through non-woven fabric (polyester and polyethylene terephthalate) Fiber, second sheet formed of basis weight: 30 g / m 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the central part), acrylic high absorption polymer (basis weight: 15 g / m 2 ) And, it was formed from an absorbent including a tissue as a core wrap, a water repellent treated side sheet, and a back sheet made of polyethylene film.
  • an absorbent including a tissue as a core wrap, a water repellent treated side sheet, and a back sheet made of polyethylene film.
  • Triethylene CL oil fatty acid glycerides, manufactured by NOF Corporation C 8 fatty acid: fatty acid of C 12 is approximately included in a weight ratio of 44:56, triesters of glycerin and fatty acid, the weight average molecular weight: about 570
  • -Panaceto 800 B manufactured by NOF Corporation Triester of glycerin and fatty acid in which all fatty acids are 2-ethylhexanoic acid (C 8 ), weight average molecular weight: about 470 NA36, manufactured by NOF Corporation C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated fatty acids and unsaturated fatty acids) in a weight ratio of approximately 5: 92: 3, Triester of glycerin and fatty acid, weight average molecular weight: about 880
  • Tricot oil fatty acid glyceride manufactured by NOF Corporation C 8 fatty acid: C 10 fatty acid: C 12 fatty acid: C 14 fatty acid: C 16 fatty acid (including both saturated fatty acid and unsaturated fatty acid) is approximately 4 Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670 ⁇ Caprylic diglyceride, manufactured by NOF Corporation Diester of glycerin and fatty acid wherein fatty acid is octanoic acid, weight average molecular weight: 340
  • Uniol D-4000 polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 4,000 Uniol PB500, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 500 Uniol PB700, manufactured by NOF Corporation, polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700
  • Uniol PB 1000 R polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1000 [Ester of (e 2 ) polyoxy C 2 -C 6 alkylene glycol with at least one fatty acid] ⁇ Wilbright cp 9, a compound in which OH groups at both ends of polybutylene glycol manufactured by NOF Corporation were esterified with hexadecanoic acid (C 16 ), weight average molecular weight: about 1,150
  • UNIOL TG-3000 glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 3,000 ⁇ UNIOL TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000
  • -PEG 1500 polyethylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,500 to about 1,600 Nonion S-6, manufactured by NOF Corporation, polyoxyethylene monostearate, repeating unit of about 7 weight average molecular weight: about 880 Will Bright s 753, manufactured by NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960
  • TG-330 a glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 6 repeating units, weight average molecular weight: about 330 ⁇ UNIOL TG-1000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 1,000
  • Unirube DGP-700 a diglyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 9 repeating units, weight average molecular weight: about 700 -Uniox HC60, manufactured by NOF Co., Ltd. polyoxyethylene hydrogenated castor oil, weight average molecular weight: about 3,570 ⁇ Vaseline, Cognis Japan Ltd. Petroleum derived hydrocarbon, semi-solid
  • the IOB, melting point and water solubility of the above sample are shown in Table 2 below.
  • the water solubility was measured according to the above-mentioned method, but 20.0 g was added to 100 g of demineralized water, and a sample dissolved after 24 hours was evaluated as "20 g ⁇ ", and 100 g of demineralized water was used. A sample in which 0.05 g was dissolved but not 1.00 g was evaluated as 0.05 to 1.00 g.
  • fusing point " ⁇ 45" means that melting
  • the skin contact surface of the top sheet of the above-mentioned sanitary napkin was coated with the above-mentioned blood modifier. Heat each blood modifier to its melting point + 20 ° C if the blood modifier is liquid at room temperature, and if the blood modifier is solid at room temperature, then control seam HMA gun Each blood modifying agent was atomized and applied to the entire skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 .
  • FIG. 14 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin (No. 2-5) in which the top sheet contains avian C2L oil fatty acid glyceride. As apparent from FIG. 14, the tri-C2L oil fatty acid glyceride is in the form of fine particles and adheres to the surface of the fiber. Rewet rates and absorber transfer rates were measured according to the procedure described above. The results are shown in Table 2 below.
  • Rewet rate (%) 100 ⁇ (weight of filter paper after test ⁇ weight of original filter paper) / 6
  • absorber transfer speed which is the time for blood to transfer from the top sheet to the absorber after the second drop of blood.
  • absorber transfer rate means the time from when blood is introduced into the top sheet to when the red color of blood is not seen on the surface and inside of the top sheet.
  • the rewet rate was 22.7% and the absorber transfer rate was over 60 seconds, but both the glycerin and fatty acid triesters had rewet rates From the fact that it is 7.0% or less and the absorber transfer rate is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among triesters of glycerin and fatty acid, NA50 of which the melting point exceeds 45 ° C. shows no significant improvement in the absorption performance.
  • a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and an aqueous solubility of about 0.00 to about 0.05 g per 100 g of water at 25 ° C. It was found that the absorption performance was greatly improved.
  • sanitary napkins were worn by a plurality of volunteer subjects.
  • sanitary napkins containing blood modifiers 2-1 to 2-3 there was no tackiness on the top sheet even after menstrual blood absorption, and it was answered that the top sheet was smooth. .
  • Defibrillation blood after blood collection, stirred for about 5 minutes in an Erlenmeyer flask together with glass beads
  • EDTA blood Addition of 0.5 mL of 12% EDTA ⁇ 2K saline to 65 mL of venous blood
  • Serum or plasma Supernatant after centrifuging defibrillated blood or EDTA blood, respectively, at about 1900 G at room temperature for 10 minutes
  • Blood cells Remove the serum from the blood and remove the residual phosphate buffered saline (PBS) ) Washed twice and then added with phosphate buffered saline for the removed serum
  • An absorbent article was produced in the same manner as in Example 2 except that avian C2L oil fatty acid glyceride was applied so as to give a basis weight of approximately 5 g / m 2, and the rewet rate was evaluated for the above various blood. . Three measurements were taken for each blood and the mean value was taken. The results are shown in Table 3 below.
  • Example 2 The same tendency as equine EDTA blood obtained in Example 2 was also obtained in human and sheep blood. The same tendency was also observed in defibrinated blood and EDTA blood.
  • the top sheet containing the blood modifying agent has low blood retention and can be rapidly transferred to the absorber after absorbing blood.
  • Example 4 [Viscosity of blood containing blood modifying agent] The viscosity of the blood containing the blood modifying agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by weight of Panaceto 810s was added to equine defibrinated blood, the mixture was lightly stirred to form a sample, the sample was loaded on a parallel plate of 50 mm in diameter, the gap was made 100 ⁇ m, and the viscosity was measured at 37 ⁇ 0.5 ° C. . Because of the parallel plate, the sample was not subjected to a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁇ 1 .
  • the viscosity of horse-defibrillated blood containing 2% by mass of Panaceto 810s was 5.9 mPa ⁇ s, while the viscosity of horse-defibrillated blood containing no blood modifying agent was 50.4 mPa ⁇ s.
  • equine defibrinated blood containing 2% by weight of Panaceto 810s reduces the viscosity by about 90% as compared to the case without blood modifying agent.
  • blood contains components such as blood cells and is known to have thixotropy properties, it is considered that the blood modifying agent of the present disclosure can lower the viscosity of blood in a low viscosity region. By reducing the viscosity of blood, it is thought that absorbed menstrual blood can be rapidly transferred from the top sheet to the absorber.
  • Example 5 [Micrograph of blood containing blood modifier] A healthy volunteer's menstrual blood is collected on Saran wrap (trademark), and a portion of it is Panaseto 810s dispersed in 10 times mass phosphate buffered saline, and the concentration of Panaceto 810s is 1% by mass. Added to The menstrual blood was applied to a slide glass, covered with a cover glass, and the condition of red blood cells was observed with a light microscope. A photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 15 (a), and a photomicrograph of menstrual blood containing PANACET 810s is shown in FIG. 15 (b).
  • red blood cells form a lump of rhomsen, etc., but in menstrual blood containing PANACET 810s, each red blood cell is stably dispersed. I understand. Therefore, it is suggested that the blood modifying agent works to stabilize red blood cells in the blood.
  • Example 6 [Surface tension of blood containing blood modifier] The surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently. The measurement is automatically performed by the device, but the density ⁇ is obtained by the following equation (see FIG. 16).
  • the density ⁇ is the density test method and density / mass / volume conversion table in JIS K 2249-1995, 5. It was measured at the temperature shown in Table 5 below according to the vibrational density test method. For measurement, DA-505 of Kyoto Electronics Industries Ltd. was used. The results are shown in Table 5.
  • the blood modifying agent has a water solubility of about 0.00 to about 0.05 g per 100 g of water at 25 ° C., but its solubility in water is very low. It can be seen that the surface tension of the blood can be reduced. By lowering the surface tension of the blood, it is considered that the absorbed blood can be rapidly transferred to the absorber without being held between the fibers of the top sheet.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/JP2013/054369 2012-03-30 2013-02-21 吸収性物品 WO2013145966A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380028095.1A CN104334134B (zh) 2012-03-30 2013-02-21 吸收性物品

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-082256 2012-03-30
JP2012082256A JP5925015B2 (ja) 2012-03-30 2012-03-30 吸収性物品

Publications (1)

Publication Number Publication Date
WO2013145966A1 true WO2013145966A1 (ja) 2013-10-03

Family

ID=49259246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/054369 WO2013145966A1 (ja) 2012-03-30 2013-02-21 吸収性物品

Country Status (5)

Country Link
JP (1) JP5925015B2 (zh)
CN (1) CN104334134B (zh)
AR (1) AR090521A1 (zh)
TW (1) TWI577350B (zh)
WO (1) WO2013145966A1 (zh)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858768B2 (en) 2015-07-31 2020-12-08 The Procter & Gamble Company Shaped nonwoven
US10888471B2 (en) 2016-12-15 2021-01-12 The Procter & Gamble Company Shaped nonwoven
US10934645B2 (en) 2017-01-31 2021-03-02 The Procter & Gamble Company Shaped nonwoven
US11090197B2 (en) 2017-01-31 2021-08-17 The Procter & Gamble Company Shaped nonwoven
US11149360B2 (en) 2017-06-30 2021-10-19 The Procter & Gamble Company Method for making a shaped nonwoven
US11160694B2 (en) 2017-01-31 2021-11-02 The Procter & Gamble Company Three-dimensional substrates and absorbent articles having the same
US11214893B2 (en) 2017-06-30 2022-01-04 The Procter & Gamble Company Shaped nonwoven
US11401640B2 (en) 2015-07-31 2022-08-02 The Procter & Gamble Company Forming belt for shaped nonwoven
US11505884B2 (en) 2019-03-18 2022-11-22 The Procter & Gamble Company Shaped nonwovens that exhibit high visual resolution
US11547613B2 (en) 2017-12-05 2023-01-10 The Procter & Gamble Company Stretch laminate with beamed elastics and formed nonwoven layer
US11655563B2 (en) 2016-04-29 2023-05-23 The Procter & Gamble Company Apparatus for making nonwoven from continuous filaments
US11819393B2 (en) 2019-06-19 2023-11-21 The Procter & Gamble Company Absorbent article with function-formed topsheet, and method for manufacturing
US11826230B2 (en) 2015-07-31 2023-11-28 The Procter & Gamble Company Package of absorbent articles utilizing a shaped nonwoven
US11850128B2 (en) 2018-09-27 2023-12-26 The Procter And Gamble Company Garment-like absorbent articles
US11896466B2 (en) 2018-06-12 2024-02-13 The Procter & Gamble Company Absorbent articles having shaped, soft and textured nonwoven fabrics
US11969325B2 (en) 2018-01-25 2024-04-30 The Procter & Gamble Company Absorbent article with function-formed topsheet, and method for manufacturing
US11999150B2 (en) 2019-05-03 2024-06-04 The Procter & Gamble Company Nonwoven webs with one or more repeat units

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6045655B1 (ja) * 2015-06-30 2016-12-14 ユニ・チャーム株式会社 吸収性物品
JP6414348B2 (ja) * 2017-01-17 2018-10-31 王子ホールディングス株式会社 吸収性物品
JP7313320B2 (ja) * 2020-08-25 2023-07-24 大王製紙株式会社 個装吸収性物品

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007130178A (ja) * 2005-11-09 2007-05-31 Kao Corp 吸収性物品用の立体シート
JP2010526631A (ja) * 2007-05-15 2010-08-05 ザ プロクター アンド ギャンブル カンパニー 着色ローション含有シートを有する吸収性物品
JP2011030700A (ja) * 2009-07-31 2011-02-17 Daio Paper Corp 吸収性物品
JP2011067484A (ja) * 2009-09-28 2011-04-07 Kao Corp 吸収性物品
JP2011072650A (ja) * 2009-09-30 2011-04-14 Daio Paper Corp 吸収性物品
JP2011080178A (ja) * 2009-10-09 2011-04-21 Unicharm Corp 不織布

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005557B2 (en) * 2001-07-03 2006-02-28 The Procter & Gamble Company Film-forming compositions for protecting skin from body fluids and articles made therefrom
JP4451029B2 (ja) * 2001-07-25 2010-04-14 ユニ・チャーム株式会社 使い捨ての体液吸収性着用物品
US20030082219A1 (en) * 2001-10-01 2003-05-01 The Procter & Gamble Company Skin care compositions comprising low concentrations of skin treatment agents
JP2003192563A (ja) * 2001-12-26 2003-07-09 Lion Corp 含浸用組成物、皮膚保護用含浸体
CA2706867C (en) * 2004-06-21 2011-04-12 The Procter & Gamble Company Absorbent article with lotion-containing topsheet
JP4799012B2 (ja) * 2005-03-10 2011-10-19 株式会社 資生堂 油性固型化粧料
JP2006233405A (ja) * 2005-08-16 2006-09-07 Asahi Kasei Chemicals Corp 繊維処理剤
JP4980685B2 (ja) * 2006-09-29 2012-07-18 大王製紙株式会社 吸収性物品
JP4812614B2 (ja) * 2006-12-27 2011-11-09 花王株式会社 吸収性物品
US20090030391A1 (en) * 2007-07-25 2009-01-29 John Lee Hammons Absorbent article
JP5268416B2 (ja) * 2008-05-01 2013-08-21 大王製紙株式会社 吸収性物品の製造方法
JP6092508B2 (ja) * 2011-09-30 2017-03-08 ユニ・チャーム株式会社 吸収性物品

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007130178A (ja) * 2005-11-09 2007-05-31 Kao Corp 吸収性物品用の立体シート
JP2010526631A (ja) * 2007-05-15 2010-08-05 ザ プロクター アンド ギャンブル カンパニー 着色ローション含有シートを有する吸収性物品
JP2011030700A (ja) * 2009-07-31 2011-02-17 Daio Paper Corp 吸収性物品
JP2011067484A (ja) * 2009-09-28 2011-04-07 Kao Corp 吸収性物品
JP2011072650A (ja) * 2009-09-30 2011-04-14 Daio Paper Corp 吸収性物品
JP2011080178A (ja) * 2009-10-09 2011-04-21 Unicharm Corp 不織布

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401640B2 (en) 2015-07-31 2022-08-02 The Procter & Gamble Company Forming belt for shaped nonwoven
US11925541B2 (en) 2015-07-31 2024-03-12 The Procter & Gamble Company Package of absorbent articles utilizing a shaped nonwoven
US11826230B2 (en) 2015-07-31 2023-11-28 The Procter & Gamble Company Package of absorbent articles utilizing a shaped nonwoven
US10858768B2 (en) 2015-07-31 2020-12-08 The Procter & Gamble Company Shaped nonwoven
US11655563B2 (en) 2016-04-29 2023-05-23 The Procter & Gamble Company Apparatus for making nonwoven from continuous filaments
US10888471B2 (en) 2016-12-15 2021-01-12 The Procter & Gamble Company Shaped nonwoven
US11730638B2 (en) 2016-12-15 2023-08-22 The Procter & Gamble Company Shaped nonwoven
US11666488B2 (en) 2017-01-31 2023-06-06 The Procter & Gamble Company Shaped nonwoven
US10934645B2 (en) 2017-01-31 2021-03-02 The Procter & Gamble Company Shaped nonwoven
US11992393B2 (en) 2017-01-31 2024-05-28 The Procter & Gamble Company Shaped nonwoven
US11427943B2 (en) 2017-01-31 2022-08-30 The Procter & Gamble Company Shaped nonwoven
US11987917B2 (en) 2017-01-31 2024-05-21 The Procter & Gamble Company Shaped nonwoven
US11324641B2 (en) 2017-01-31 2022-05-10 The Procter & Gamble Company Shaped nonwoven
US11872112B2 (en) 2017-01-31 2024-01-16 The Procter & Gamble Company Shaped nonwoven
US11160694B2 (en) 2017-01-31 2021-11-02 The Procter & Gamble Company Three-dimensional substrates and absorbent articles having the same
US11661689B2 (en) 2017-01-31 2023-05-30 The Procter & Gamble Company Shaped nonwoven
US10968552B2 (en) 2017-01-31 2021-04-06 The Procter & Gamble Company Shaped nonwoven
US11090197B2 (en) 2017-01-31 2021-08-17 The Procter & Gamble Company Shaped nonwoven
US11773521B2 (en) 2017-01-31 2023-10-03 The Procter & Gamble Company Shaped nonwoven
US11939701B2 (en) 2017-06-30 2024-03-26 The Procter & Gamble Company Shaped nonwoven
US11214893B2 (en) 2017-06-30 2022-01-04 The Procter & Gamble Company Shaped nonwoven
US11149360B2 (en) 2017-06-30 2021-10-19 The Procter & Gamble Company Method for making a shaped nonwoven
US11746441B2 (en) 2017-06-30 2023-09-05 The Procter & Gamble Company Method for making a shaped nonwoven
US11634838B2 (en) 2017-06-30 2023-04-25 The Procter & Gamble Company Shaped nonwoven
US11547613B2 (en) 2017-12-05 2023-01-10 The Procter & Gamble Company Stretch laminate with beamed elastics and formed nonwoven layer
US11969325B2 (en) 2018-01-25 2024-04-30 The Procter & Gamble Company Absorbent article with function-formed topsheet, and method for manufacturing
US11896466B2 (en) 2018-06-12 2024-02-13 The Procter & Gamble Company Absorbent articles having shaped, soft and textured nonwoven fabrics
US11850128B2 (en) 2018-09-27 2023-12-26 The Procter And Gamble Company Garment-like absorbent articles
US11918442B2 (en) 2018-09-27 2024-03-05 The Procter & Gamble Company Garment-like absorbent articles
US11998427B2 (en) 2018-09-27 2024-06-04 The Procter & Gamble Company Nonwoven webs with visually discernible patterns
US11505884B2 (en) 2019-03-18 2022-11-22 The Procter & Gamble Company Shaped nonwovens that exhibit high visual resolution
US11999150B2 (en) 2019-05-03 2024-06-04 The Procter & Gamble Company Nonwoven webs with one or more repeat units
US11819393B2 (en) 2019-06-19 2023-11-21 The Procter & Gamble Company Absorbent article with function-formed topsheet, and method for manufacturing

Also Published As

Publication number Publication date
TW201402082A (zh) 2014-01-16
JP2013208384A (ja) 2013-10-10
CN104334134A (zh) 2015-02-04
AR090521A1 (es) 2014-11-19
TWI577350B (zh) 2017-04-11
CN104334134B (zh) 2016-05-11
JP5925015B2 (ja) 2016-05-25

Similar Documents

Publication Publication Date Title
WO2013145966A1 (ja) 吸収性物品
JP5713951B2 (ja) 吸収性物品
TWI551273B (zh) Absorbent items
JP5847055B2 (ja) 吸収性物品
WO2013129327A1 (ja) 吸収性物品
WO2014050595A1 (ja) 吸収性物品
JP5843740B2 (ja) 吸収性物品
JP6037606B2 (ja) 吸収性物品、吸収性物品のトップシートおよびそのトップシートの製造方法
JP5963639B2 (ja) 吸収性物品
JP5709788B2 (ja) 吸収性物品
JP5916327B2 (ja) 吸収性物品
JP6041473B2 (ja) 吸収性物品
JP5769655B2 (ja) 吸収性物品
JP6041472B2 (ja) 吸収性物品、吸収性物品のトップシートおよびそのトップシートの製造方法
JP5762346B2 (ja) 吸収性物品
JP5709789B2 (ja) 吸収性物品
JP5713950B2 (ja) 吸収性物品
WO2014050412A1 (ja) 吸収性物品
WO2013129326A1 (ja) 吸収性物品
JP2013208410A (ja) 吸収性物品
WO2013129325A1 (ja) 吸収性物品

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380028095.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13770086

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13770086

Country of ref document: EP

Kind code of ref document: A1